Literature DB >> 20404791

Liver transplantation for hepatocellular carcinoma.

Angel E Alsina1.   

Abstract

BACKGROUND: The treatment of hepatocellular carcinoma (HCC) is challenging, but transplantation of the liver has emerged as one of the options in the therapeutic armamentarium against this disease.
METHODS: This article reviews the changing criteria for patient eligibility for liver transplantation for HCC and presents an initial evaluation of institutional treatment outcomes for this treatment modality. A method for evaluating prognosis is also described.
RESULTS: Patients are considered for liver transplantation if they meet the Milan criteria for eligibility or a UCSF-attributed expansion of these criteria that includes the "rule of 7, " whereby the sum of the size of the largest nodule plus the total number of nodules cannot exceed 7. Preliminary institutional experience suggests a tumor recurrence rate of 11% in 91 patients with HCC who received liver transplants between 1996 and 2008.
CONCLUSIONS: Liver transplantation offers an opportunity for long-term survival in patients with HCC and chronic cirrhosis whose tumor cannot be resected. Criteria for patient selection for this modality of treatment continue to be upgraded and refined.

Entities:  

Mesh:

Year:  2010        PMID: 20404791     DOI: 10.1177/107327481001700203

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  5 in total

Review 1.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 2.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

3.  Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.

Authors:  Altan Alim; Yalcin Erdogan; Murat Dayangac; Yildiray Yuzer; Yaman Tokat; Arzu Oezcelik
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

4.  Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience.

Authors:  Lin Zhou; Li-Chao Pan; Yong-Gen Zheng; Guo-Sheng Du; Xiao-Qian Fu; Zhi-Dong Zhu; Ji-Yong Song; Zhi-Jia Liu; Xiang-Zheng Su; Wen Chen; De-Hua Zheng; Long-Long Suo; Shao-Zhen Yang
Journal:  Oncol Lett       Date:  2018-07-27       Impact factor: 2.967

Review 5.  CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review.

Authors:  Daniel Marin; Salvatore Cappabianca; Nicola Serra; Assunta Sica; Francesco Lassandro; Roberto D'Angelo; Michelearcangelo La Porta; Francesco Fiore; Francesco Somma
Journal:  Gastroenterol Res Pract       Date:  2015-12-22       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.